Matthew Meng Yang Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew Meng Yang Lee has a total of 453 co-authors. Here are the top co-authors by number of shared publications:
- Naveed Sattar
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom
14 shared publications - John Joseph Valentine McMurray
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
13 shared publications - Colin Berry
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
11 shared publications - Kieran F. Docherty
British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow
11 shared publications - Mark Colquhoun Petrie
School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow, Scotland
11 shared publications - Pardeep S. Jhund
British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow
11 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Elsevier in JACC: Heart Failure
Effect of Aficamten in Obstructive Hypertrophic Cardiomyopathy With Comorbidities: Obesity, Hypertension, and Diabetes
- 11 November 2026
- Published by Elsevier in JACC: Heart Failure
Open AccessEffect of Aficamten in Obstructive Hypertrophic Cardiomyopathy With Comorbidities: Obesity, Hypertension, and Diabetes
- 10 November 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (11) , 1970-1973
Ruling Out the Test, Not the Diagnosis: An Artificial Intelligence−Derived Score for Effort Intolerance Across the Heart Failure Spectrum
- 10 November 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (11) , 1970-1973
Ruling Out the Test, Not the Diagnosis: An Artificial Intelligence−Derived Score for Effort Intolerance Across the Heart Failure Spectrum
- Open Access
- 24 September 2026
- Published by Elsevier in European Journal of Internal Medicine
Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors
- 24 September 2026
- Published by Elsevier in European Journal of Internal Medicine
Open AccessMultiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors
- 6 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2579-2581
Heart failure prevention in central adiposity and preclinical left ventricular systolic impairment
- 6 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2579-2581
Heart failure prevention in central adiposity and preclinical left ventricular systolic impairment
- Open Access
- 20 May 2026
- Published by Wiley in British Journal of Clinical Pharmacology
External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
Diuretic resistance in worsening heart failure (HF) is associated with poorer outcomes and, although common, can be challenging to identify. The recently developed BAN‐ADHF score can potentially identify patients with worsening HF at risk of diuretic resistance. We externally validated the BAN‐ADHF diuretic‐resistance score in a multicentre randomized trial comparing adjunctive dapagliflozin to metolazone in patients with HF and diuretic resistance. We calculated a seven‐variable modified BAN‐ADHF score at baseline and dichotomised patients by the median BAN‐ADHF score (8). We assessed loop diuretic efficiency (kg weight change per 40‐mg furosemide) and decongestion (weight, eight‐zone lung ultrasound B‐lines, clinical congestion score) over 96 h. A baseline score ≥8 identified lower loop diuretic efficiency (pooled difference −0.12 kg/40 mg, 95% CI −0.18 to −0.06; p < 0.001) despite similar congestion markers at baseline. The BAN‐ADHF score may be useful clinically to identify patients at risk of diminished response to diuretics.
- 20 May 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessExternal validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
Diuretic resistance in worsening heart failure (HF) is associated with poorer outcomes and, although common, can be challenging to identify. The recently developed BAN‐ADHF score can potentially identify patients with worsening HF at risk of diuretic resistance. We externally validated the BAN‐ADHF diuretic‐resistance score in a multicentre randomized trial comparing adjunctive dapagliflozin to metolazone in patients with HF and diuretic resistance. We calculated a seven‐variable modified BAN‐ADHF score at baseline and dichotomised patients by the median BAN‐ADHF score (8). We assessed loop diuretic efficiency (kg weight change per 40‐mg furosemide) and decongestion (weight, eight‐zone lung ultrasound B‐lines, clinical congestion score) over 96 h. A baseline score ≥8 identified lower loop diuretic efficiency (pooled difference −0.12 kg/40 mg, 95% CI −0.18 to −0.06; p < 0.001) despite similar congestion markers at baseline. The BAN‐ADHF score may be useful clinically to identify patients at risk of diminished response to diuretics.
- 28 March 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Rethinking decongestion in HFpEF: when less diuretic means more disease modification
Matthew M Y Lee, Jan Biegus, Bernhard Haring; Rethinking Decongestion in HFpEF: When Less Diuretic Means More Disease Modification, European Journal of Hea
- 28 March 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Rethinking decongestion in HFpEF: when less diuretic means more disease modification
Matthew M Y Lee, Jan Biegus, Bernhard Haring; Rethinking Decongestion in HFpEF: When Less Diuretic Means More Disease Modification, European Journal of Hea
- 18 February 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Do we need exercise echocardiography to diagnose HFpEF? Not at all
Alice Brennan, Ross T Campbell, Kieran F Docherty, Matthew M Y Lee, John J V McMurray, John G F Cleland, Mark C Petrie, Pierpaolo Pellicori; Do we need exe
- 18 February 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Do we need exercise echocardiography to diagnose HFpEF? Not at all
Alice Brennan, Ross T Campbell, Kieran F Docherty, Matthew M Y Lee, John J V McMurray, John G F Cleland, Mark C Petrie, Pierpaolo Pellicori; Do we need exe
- 1 February 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (2) , 165-168
What’s new in heart failure? February 2026
Matthew M Y Lee, Daniela Tomasoni, Alberto Aimo; What’s New in Heart Failure? February 2026, European Journal of Heart Failure, , xuag107, https://doi.org/
- 1 February 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (2) , 165-168
What’s new in heart failure? February 2026
Matthew M Y Lee, Daniela Tomasoni, Alberto Aimo; What’s New in Heart Failure? February 2026, European Journal of Heart Failure, , xuag107, https://doi.org/
- Open Access
- 13 October 2025
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 94, 16-26
Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials
- 13 October 2025
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 94, 16-26
Open AccessEfficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials